Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Goldman

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
British Journal of Haematology|November 14, 2013
Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side effectsPratap Neelakantan, Katayoun Rezvani, Philippa May, et al.
American Journal of Hematology|June 23, 2009
Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemiaLetizia Foroni, Gareth Gerrard, Emmanuel Nna, et al.
Blood|August 14, 2010
Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal responseAya Kuwabara, Anna Babb, Amr Ibrahim, et al.
Haematologica|August 24, 2011
Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failedAmr R Ibrahim, Richard E Clark, Tessa L Holyoake, et al.
Blood|December 17, 2011
Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patientsDragana Milojkovic, Jane F Apperley, Gareth Gerrard, et al.
American Journal of Hematology|February 18, 2011
Duplex quantitative PCR for molecular monitoring of BCR-ABL1-associated hematological malignanciesGareth Gerrard, Katherine Mudge, Rebecca Stewart, et al.
Haematologica|January 19, 2011
The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issuesRichard A Van Etten, Steffen Koschmieder, Francois Delhommeau, et al.
Blood|February 6, 2013
Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategiesPratap Neelakantan, Gareth Gerrard, Claire Lucas, et al.
Frontiers in Cellular and Infection Microbiology|August 6, 2021
A Metatranscriptomics Survey of Microbial Diversity on Surfaces Post-Intervention of cleanSURFACES® Technology in an Intensive Care UnitJeremy Chen See, Truc Ly, Alexander Shope, et al.
American Journal of Hematology|January 11, 2012
BCR-ABL1 kinase domain mutations: methodology and clinical evaluationMary Alikian, Gareth Gerrard, Papagudi G Subramanian, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
British Journal of Haematology|November 14, 2013
Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side effectsPratap Neelakantan, Katayoun Rezvani, Philippa May, et al.
American Journal of Hematology|June 23, 2009
Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemiaLetizia Foroni, Gareth Gerrard, Emmanuel Nna, et al.
Blood|August 14, 2010
Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal responseAya Kuwabara, Anna Babb, Amr Ibrahim, et al.
Haematologica|August 24, 2011
Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failedAmr R Ibrahim, Richard E Clark, Tessa L Holyoake, et al.
Blood|December 17, 2011
Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patientsDragana Milojkovic, Jane F Apperley, Gareth Gerrard, et al.
American Journal of Hematology|February 18, 2011
Duplex quantitative PCR for molecular monitoring of BCR-ABL1-associated hematological malignanciesGareth Gerrard, Katherine Mudge, Rebecca Stewart, et al.
Haematologica|January 19, 2011
The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issuesRichard A Van Etten, Steffen Koschmieder, Francois Delhommeau, et al.
Blood|February 6, 2013
Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategiesPratap Neelakantan, Gareth Gerrard, Claire Lucas, et al.
Frontiers in Cellular and Infection Microbiology|August 6, 2021
A Metatranscriptomics Survey of Microbial Diversity on Surfaces Post-Intervention of cleanSURFACES® Technology in an Intensive Care UnitJeremy Chen See, Truc Ly, Alexander Shope, et al.
American Journal of Hematology|January 11, 2012
BCR-ABL1 kinase domain mutations: methodology and clinical evaluationMary Alikian, Gareth Gerrard, Papagudi G Subramanian, et al.
Pageof 6